Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
02 08 2021
Historique:
received: 09 12 2020
accepted: 16 06 2021
pubmed: 23 6 2021
medline: 21 10 2021
entrez: 22 6 2021
Statut: ppublish

Résumé

Broadly reactive antibodies targeting the influenza A virus hemagglutinin (HA) head domain are thought to be rare and to require extensive somatic mutations or unusual structural features to achieve breadth against divergent HA subtypes. Here we describe common genetic and structural features of protective human antibodies from several individuals recognizing the trimer interface (TI) of the influenza A HA head, a recently identified site of vulnerability. We examined the sequence of TI-reactive antibodies, determined crystal structures for TI antibody-antigen complexes, and analyzed the contact residues of the antibodies on HA to discover common genetic and structural features of TI antibodies. Our data reveal that many TI antibodies are encoded by a light chain variable gene segment incorporating a shared somatic mutation. In addition, these antibodies have a shared acidic residue in the heavy chain despite originating from diverse heavy chain variable gene segments. These studies show that the TI region of influenza A HA is a major antigenic site with conserved structural features that are recognized by a common human B cell public clonotype. The canonical nature of this antibody-antigen interaction suggests that the TI epitope might serve as an important target for structure-based vaccine design.

Identifiants

pubmed: 34156974
pii: e146791
doi: 10.1172/JCI146791
pmc: PMC8321569
doi:
pii:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Epitopes 0
Hemagglutinin Glycoproteins, Influenza Virus 0
Influenza Vaccines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : HHSN272201400024C
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI110750
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI095202
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201700041I
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI150739
Pays : United States
Organisme : NIH HHS
ID : S10 OD023680
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI117905
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002243
Pays : United States

Références

Nat Med. 2021 Jan;27(1):106-114
pubmed: 33288923
Science. 2009 Apr 10;324(5924):246-51
pubmed: 19251591
Cell Rep. 2017 Sep 19;20(12):2935-2943
pubmed: 28930686
Acta Virol. 1999 Aug;43(4):237-44
pubmed: 10749369
Nat Immunol. 2017 Apr;18(4):456-463
pubmed: 28192417
Cell. 2016 Jul 28;166(3):609-623
pubmed: 27453470
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
J Clin Invest. 2010 May;120(5):1663-73
pubmed: 20389023
J Virol. 1983 Oct;48(1):239-48
pubmed: 6193286
J Infect Dis. 2018 Jul 2;218(3):347-354
pubmed: 29506129
Elife. 2015 Aug 07;4:
pubmed: 26252514
Cell Rep. 2020 Jan 21;30(3):905-913.e6
pubmed: 31968262
Cell Host Microbe. 2017 Oct 11;22(4):471-483.e5
pubmed: 28966056
Science. 2012 Sep 14;337(6100):1343-8
pubmed: 22878502
J Virol. 1993 Feb;67(2):933-42
pubmed: 7678310
Cell. 2016 Jul 28;166(3):596-608
pubmed: 27453466
J Infect Dis. 2001 Sep 15;184(6):665-70
pubmed: 11517426
Immunity. 2017 Oct 17;47(4):599-603
pubmed: 29045889
JAMA. 2000 Oct 4;284(13):1655-63
pubmed: 11015795
Science. 2011 Aug 12;333(6044):843-50
pubmed: 21737702
Euro Surveill. 2014 May 08;19(18):
pubmed: 24832117
Virology. 2015 May;479-480:234-46
pubmed: 25812763
Cell Host Microbe. 2020 Mar 11;27(3):418-427.e4
pubmed: 32059794
Nat Med. 2016 Dec;22(12):1456-1464
pubmed: 27820605
J Biol Chem. 2017 Mar 3;292(9):3900-3908
pubmed: 28077575
Science. 2011 Aug 12;333(6044):850-6
pubmed: 21798894
Nature. 1981 Apr 23;290(5808):713-7
pubmed: 6163993
Vaccine. 2007 Sep 28;25(39-40):6852-62
pubmed: 17719149
Cell Host Microbe. 2019 Jun 12;25(6):827-835.e6
pubmed: 31104946
Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):5986-91
pubmed: 18413603
J Virol. 2013 Jun;87(12):7149-54
pubmed: 23552413
J Virol. 1993 May;67(5):2552-8
pubmed: 7682624
PLoS Pathog. 2010 Jul 08;6(7):e1000990
pubmed: 20628565
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):445-50
pubmed: 24335589
J Clin Invest. 2013 Oct;123(10):4405-9
pubmed: 23999429
PLoS Biol. 2019 Feb 4;17(2):e3000139
pubmed: 30716060
Cell Host Microbe. 2013 Mar 13;13(3):314-23
pubmed: 23498956
Nat Med. 2019 Oct;25(10):1589-1600
pubmed: 31591605
Cell. 2019 May 16;177(5):1124-1135.e16
pubmed: 31100267
Cell. 2019 May 16;177(5):1136-1152.e18
pubmed: 31100268
Cell. 1982 Dec;31(2 Pt 1):417-27
pubmed: 6186384
J Clin Invest. 2020 Sep 1;130(9):4734-4739
pubmed: 32749241

Auteurs

Seth J Zost (SJ)

The Vanderbilt Vaccine Center and.
Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Jinhui Dong (J)

The Vanderbilt Vaccine Center and.

Iuliia M Gilchuk (IM)

The Vanderbilt Vaccine Center and.

Pavlo Gilchuk (P)

The Vanderbilt Vaccine Center and.

Natalie J Thornburg (NJ)

The Vanderbilt Vaccine Center and.

Sandhya Bangaru (S)

Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Nurgun Kose (N)

The Vanderbilt Vaccine Center and.

Jessica A Finn (JA)

The Vanderbilt Vaccine Center and.
Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Robin Bombardi (R)

The Vanderbilt Vaccine Center and.

Cinque Soto (C)

The Vanderbilt Vaccine Center and.
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Elaine C Chen (EC)

The Vanderbilt Vaccine Center and.
Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Rachel S Nargi (RS)

The Vanderbilt Vaccine Center and.

Rachel E Sutton (RE)

The Vanderbilt Vaccine Center and.

Ryan P Irving (RP)

The Vanderbilt Vaccine Center and.

Naveenchandra Suryadevara (N)

The Vanderbilt Vaccine Center and.

Jonna B Westover (JB)

Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, USA.

Robert H Carnahan (RH)

The Vanderbilt Vaccine Center and.
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Hannah L Turner (HL)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.

Sheng Li (S)

Department of Medicine and Biomedical Sciences, School of Medicine, University of California, San Diego, California, USA.

Andrew B Ward (AB)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.

James E Crowe (JE)

The Vanderbilt Vaccine Center and.
Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH